What are the dosing guidelines for oseltamivir (Tamiflu) for treatment and post‑exposure prophylaxis in adults and children, including renal dose adjustments, contraindications, and use in pregnancy?

Oseltamivir (Tamiflu) Dosing Guidelines

Treatment of Influenza

For adults and adolescents ≥13 years, administer oseltamivir 75 mg orally twice daily for 5 days, starting within 48 hours of symptom onset for maximum benefit. 1

Adult and Adolescent Dosing (≥13 years)

• Standard dose: 75 mg orally twice daily for 5 days 1
• Treatment should ideally begin within 12-24 hours of symptom onset for optimal efficacy—starting within 12 hours reduces illness duration by an additional 74.6 hours compared to treatment at 48 hours 2
• Recent observational data in hospitalized adults demonstrates that oseltamivir started on admission day significantly reduces peak pulmonary disease severity, ICU admission, organ failure, and in-hospital death 3

Pediatric Dosing (≥1 year)

Weight-based dosing twice daily for 5 days: 4, 1

• <15 kg: 30 mg twice daily
• >15-23 kg: 45 mg twice daily
• >23-40 kg: 60 mg twice daily
• >40 kg: 75 mg twice daily

Infants <1 Year

• FDA-approved for treatment in infants ≥2 weeks of age 4
• The AAP and CDC recommend oseltamivir can be used from birth (including preterm infants) as benefits likely outweigh risks 4
• Dosing for term infants: CDC recommends 3.0 mg/kg twice daily for all infants <12 months 4
• Preterm infants require lower weight-based dosing based on postmenstrual age due to immature renal function 4

---

Prophylaxis of Influenza

For post-exposure prophylaxis in adults and adolescents ≥13 years, give oseltamivir 75 mg once daily for at least 10 days after last known exposure. 1

Adult and Adolescent Prophylaxis (≥13 years)

• Post-exposure: 75 mg once daily for at least 10 days 1
• Community outbreak: 75 mg once daily for up to 6 weeks 1

Pediatric Prophylaxis (≥1 year)

Weight-based dosing once daily for 10 days: 4, 1

• <15 kg: 30 mg once daily
• >15-23 kg: 45 mg once daily
• >23-40 kg: 60 mg once daily
• >40 kg: 75 mg once daily
• Community outbreak: Same weight-based doses once daily for up to 6 weeks 4, 1

Infants <1 Year

• Not FDA-approved for prophylaxis in infants <1 year 4
• The AAP and CDC do not recommend chemoprophylaxis in infants <3 months due to limited safety and efficacy data 4

---

Renal Dose Adjustments

For patients with creatinine clearance 10-30 mL/min, reduce treatment dose to 75 mg once daily for 5 days and prophylaxis dose to 75 mg every other day or 30 mg once daily. 1

Renal Impairment Dosing

• CrCl 10-30 mL/min (treatment): 75 mg once daily for 5 days 4, 1
• CrCl 10-30 mL/min (prophylaxis): 75 mg every other day OR 30 mg once daily 1
• No dose adjustment needed for mild renal impairment 4
• No dosing recommendations available for patients on routine dialysis 4

Important Caveat on Renal Dosing

• Current renal dosing recommendations focus on steady-state concentrations but may delay achievement of therapeutic levels early in infection 5
• The first dose should be 75 mg (standard loading dose) even in renal impairment, with subsequent doses reduced according to creatinine clearance to ensure early therapeutic concentrations 5
• Pharmacokinetic modeling supports 30 mg once daily for severe impairment and 30 mg twice daily for moderate impairment to match exposures in normal renal function 6

---

Special Populations

Pregnancy

• No adequate data in pregnant women; use only if clearly needed 1
• The FDA label advises caution but does not contraindicate use when benefits outweigh risks 1

Nursing Mothers

• Caution should be exercised when administering to nursing women 1

Elderly (>65 years)

• No dose reduction required based on age alone 4

Hepatic Impairment

• Not studied in patients with hepatic dysfunction; no specific dosing recommendations available 4

Obesity/Large Body Mass

• Standard 75 mg dosing may be inadequate in patients with large body mass 5
• Consider proportionately larger first dose based on body mass, with therapeutic drug monitoring if available 5

---

Contraindications

Oseltamivir is contraindicated in patients with known serious hypersensitivity to oseltamivir or any component of Tamiflu. 1

• Hypersensitivity reactions including anaphylaxis have been reported post-marketing 4, 1

---

Administration

• Can be administered orally without regard to meals, though taking with food may improve gastrointestinal tolerability 4
• Available formulations: 30 mg, 45 mg, and 75 mg capsules; powder for oral suspension (6 mg/mL final concentration) 4, 1
• If commercial suspension unavailable, pharmacies can compound suspension per package label instructions 4
• For infants <1 year, use appropriate measuring device (3 mL or 5 mL oral syringe) instead of supplied syringe 4

---

Key Warnings and Adverse Events

Neuropsychiatric Events

• Patients with influenza, particularly pediatric patients, may be at increased risk of confusion or abnormal behavior early in illness 1
• Monitor for signs of abnormal behavior; seizure events reported post-marketing 4, 1
• Prophylaxis studies showed dose-response effect on psychiatric events (P=0.038) 7

Common Adverse Events

• Treatment in adults: Nausea (NNTH 28) and vomiting (NNTH 22) 7
• Treatment in children: Vomiting (NNTH 19) 7
• Prophylaxis: Nausea (NNTH 25), headaches (NNTH 32), and increased risk of psychiatric events (NNTH 94) 7

Serious Skin/Hypersensitivity Reactions

• Discontinue oseltamivir immediately and initiate appropriate treatment if allergic-like reactions occur 1

---

Drug Interactions

Do not administer live attenuated influenza vaccine (intranasal) until 48 hours after stopping oseltamivir; do not give oseltamivir until 2 weeks after intranasal vaccine unless medically indicated. 1

---

Clinical Efficacy Considerations

Benefits

• Reduces time to symptom alleviation by 16.8 hours in adults and 29 hours in otherwise healthy children 7
• Reduces investigator-mediated unverified pneumonia by 1% (NNTB 100) in adults, though effect not significant in trials using detailed diagnostic criteria 7
• In prophylaxis, reduces symptomatic influenza by 55% (NNTB 33) and household transmission by 13.6% (NNTB 7) 7
• Observational data in hospitalized adults shows significant reduction in disease progression and mortality when started on admission day 3

Limitations

• No evidence of reduced hospital admissions in treatment trials 7
• No significant effect on verified bacterial complications (bronchitis, otitis media, sinusitis) 7
• Efficacy not established if treatment begins >48 hours after symptom onset 1
• Not a substitute for annual influenza vaccination 1
• Recent survey data shows significant variability in clinician adherence to treatment guidelines for hospitalized children, with only 49.5% of eligible cases receiving oseltamivir 8